

Ethan M Basch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006953/publications.pdf>

Version: 2024-02-01

294
papers

31,428
citations

8181

76
h-index

4885

168
g-index

300
all docs

300
docs citations

300
times ranked

29187
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 311-320.	1.2	5
2	Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning subscale among patients with advanced or metastatic breast cancer. <i>Cancer</i> , 2022, 128, 808-818.	4.1	6
3	An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment. <i>Value in Health</i> , 2022, 25, 1081-1086.	0.3	9
4	eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100137.	2.1	19
5	Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). <i>Cancer</i> , 2022, 128, 1242-1251.	4.1	11
6	Reply to "Another look at floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning subscale and possible solutions". <i>Cancer</i> , 2022, 128, 2386-2387.	4.1	0
7	Evaluating the implementation and impact of navigator-supported remote symptom monitoring and management: a protocol for a hybrid type 2 clinical trial. <i>BMC Health Services Research</i> , 2022, 22, 538.	2.2	5
8	Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials. <i>Clinical Trials</i> , 2022, 19, 274-276.	1.6	3
9	Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2413.	7.4	108
10	A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring. <i>Current Oncology</i> , 2022, 29, 4370-4385.	2.2	14
11	Racial differences in user experiences and perceived value of electronic symptom monitoring in a cohort of black and white bladder and prostate cancer patients. <i>Quality of Life Research</i> , 2021, 30, 3213-3227.	3.1	12
12	The association between patient experience and healthcare outcomes using SEER-CAHPS patient experience and outcomes among cancer survivors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 623-631.	1.0	7
13	Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Clinical Trials</i> , 2021, 18, 104-114.	1.6	80
14	Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2021, 127, 957-967.	4.1	7
15	Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 77.e1-77.e8.	1.6	6
16	Electronic Patient-Reported Outcomes After Thoracic Surgery: Toward Better Remote Management of Perioperative Symptoms. <i>Annals of Surgical Oncology</i> , 2021, 28, 1878-1879.	1.5	4
17	Improving patient-reported measures in oncology: a payer call to action. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 118-126.	0.9	8
18	Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 943-944.	6.3	14

#	ARTICLE	IF	CITATIONS
19	Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2021, 39, 701-703.	1.6	16
20	Broadened Eligibility for Lung Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 939.	7.4	14
21	Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer. <i>Clinical Trials</i> , 2021, 18, 408-416.	1.6	4
22	Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. <i>JAMA Health Forum</i> , 2021, 2, e210673.	2.2	0
23	Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy. <i>Cancer</i> , 2021, 127, 2980-2989.	4.1	17
24	Implementation of Electronic Patient-Reported Outcomes for Symptom Monitoring in a Large Multisite Community Oncology Practice: Dancing the Texas Two-Step Through a Pandemic. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 615-621.	2.1	34
25	A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0253021.	2.5	6
26	Stakeholder Perceptions of Key Aspects of High-Quality Cancer Care to Assess with Patient Reported Outcome Measures: A Systematic Review. <i>Cancers</i> , 2021, 13, 3628.	3.7	6
27	Use of an Analytics and Electronic Health Record-Based Approach for Targeted COVID-19 Vaccine Outreach to Marginalized Populations. <i>JAMA Oncology</i> , 2021, 7, 1570.	7.1	3
28	Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS domains. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29257.	1.5	6
29	Patient-Reported Outcomes Integrated Within an Electronic Medical Record in Patients With Head and Neck Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 842-848.	2.1	4
30	Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2. <i>Quality of Life Research</i> , 2021, , 1.	3.1	5
31	Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39). <i>Lung Cancer</i> , 2021, 162, 1-8.	2.0	9
32	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 447-456.	1.9	3
33	Targetable Action Points to Enhance Surgical Decision-Making. <i>Journal of the American College of Surgeons</i> , 2021, 233, e105.	0.5	0
34	Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. <i>JAMA Oncology</i> , 2020, 6, e193332.	7.1	39
35	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. <i>European Urology Oncology</i> , 2020, 3, 540-543.	5.4	13
36	Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials. <i>JAMA Oncology</i> , 2020, 6, 437.	7.1	22

#	ARTICLE	IF	CITATIONS
37	Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1055-1062.	6.3	9
38	Adding Patient-Reported Outcomes to Medicare's Oncology Value-Based Payment Model. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 213.	7.4	36
39	Population-level evidence of survival benefits of patient-reported outcome symptom monitoring software systems in routine cancer care. <i>Cancer Medicine</i> , 2020, 9, 7797-7799.	2.8	15
40	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 2782-2797.	1.6	201
41	Supervision Requirements in the 2020 Hospital Outpatient Prospective Payment System. <i>JAMA Oncology</i> , 2020, 6, 819.	7.1	3
42	Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 947-957.	2.1	97
43	Use of Patient-Reported Outcomes to Understand & Measure the Patient Experience of Novel Cell and Gene Therapies. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1566-1575.	1.6	6
44	Electronic Patient-Reported Outcomes as Digital Therapeutics to Improve Cancer Outcomes. <i>JCO Oncology Practice</i> , 2020, 16, 541-542.	2.9	22
45	Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. <i>Cancer Medicine</i> , 2020, 9, 3078-3087.	2.8	20
46	Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers. <i>JCO Oncology Practice</i> , 2020, 16, e234-e250.	2.9	7
47	Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020, 18, 378-386.e1.	1.9	15
48	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. <i>Lancet Oncology</i> , The, 2020, 21, e83-e96.	10.7	180
49	Oncology Practice During the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2005.	7.4	221
50	Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2020, 126, 3084-3093.	4.1	25
51	Nurse, oncologist, and patient impressions of electronic symptom monitoring via patient-reported outcomes in community oncology practices: Qualitative results from the U.S. national PRO-TECT trial (AFT-39, NCT03249090).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7044-7044.	1.6	1
52	Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017. <i>JAMA Oncology</i> , 2019, 5, 1358.	7.1	13
53	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1518-1530.	10.7	69
54	Stakeholder perspectives on addressing adverse events from adjuvant cancer therapy: A qualitative study. <i>Cancer</i> , 2019, 125, 4471-4480.	4.1	2

#	ARTICLE	IF	CITATIONS
55	Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 731-732.	46.4	59
56	Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 306.	7.4	363
57	Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1012-1020.	1.1	85
58	Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. <i>Cancer</i> , 2019, 125, 2945-2954.	4.1	60
59	Older Adults with Cancer: A Randomized Controlled Trial of Occupational and Physical Therapy. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 953-960.	2.6	35
60	Commentary on King-Kallimanis et al.: Inadequate measurement of symptomatic adverse events in immunotherapy registration trials. <i>Clinical Trials</i> , 2019, 16, 327-328.	1.6	2
61	High Compliance Rates With Patient-Reported Outcomes in Oncology Trials Submitted to the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2019, 111, 437-439.	6.3	17
62	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. <i>Oncologist</i> , 2019, 24, 762-771.	3.7	56
63	The Evolving Uses of "Real-World" Data. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1359.	7.4	35
64	Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2019, 27, 4525-4534.	2.2	10
65	Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 276-285.	4.4	46
66	Ambulatory cancer care electronic symptom self-reporting (ACCESS) for surgical patients: a randomised controlled trial protocol. <i>BMJ Open</i> , 2019, 9, e030863.	1.9	24
67	Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery. <i>Medical Care</i> , 2019, 57, S92-S99.	2.4	40
68	Association Between Reimbursement Incentives and Physician Practice in Oncology. <i>JAMA Oncology</i> , 2019, 5, 893.	7.1	28
69	Patient-reported outcome monitoring in a routine paediatric oncology setting: challenges and opportunities. <i>Lancet Oncology</i> , The, 2019, 20, 19-20.	10.7	5
70	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , 2019, 75, 929-937.	1.9	41
71	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). <i>Clinical Trials</i> , 2019, 16, 165-175.	1.6	52
72	Relationship between sleep and exercise as colorectal cancer survivors transition off treatment. <i>Supportive Care in Cancer</i> , 2018, 26, 2663-2673.	2.2	8

#	ARTICLE	IF	CITATIONS
73	Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols. JAMA - Journal of the American Medical Association, 2018, 319, 483.	7.4	507
74	Patient-reported outcomes: an essential component of oncology drug development and regulatory review. Lancet Oncology, The, 2018, 19, 595-597.	10.7	30
75	Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA Oncology, 2018, 4, 580.	7.1	19
76	A qualitative study of patient and provider perspectives on using web-based pain coping skills training to treat persistent cancer pain. Palliative and Supportive Care, 2018, 16, 155-169.	1.0	6
77	Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. Journal of Oncology Pharmacy Practice, 2018, 24, 424-432.	0.9	15
78	Symptom Monitoring in Pediatric Oncology Using Patient-Reported Outcomes: Why, How, and Where Next. Patient, 2018, 11, 147-153.	2.7	57
79	Strategies to Achieve High-Value Oncology Care—A Beginning. JAMA Oncology, 2018, 4, 171.	7.1	2
80	Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value in Health, 2018, 21, 742-747.	0.3	79
81	Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. JAMA Oncology, 2018, 4, e173598.	7.1	31
82	Implementation of Patient-Reported Outcomes in Routine Medical Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 122-134.	3.8	260
83	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1521-1539.	1.6	51
84	Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. Journal of Clinical Oncology, 2018, 36, 3120-3125.	1.6	45
85	Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. Journal of Patient-Reported Outcomes, 2018, 2, 56.	1.9	4
86	Oncology in Transition. JAMA - Journal of the American Medical Association, 2018, 320, 2203.	7.4	4
87	Sorafenib for Advanced and Refractory Desmoid Tumors. New England Journal of Medicine, 2018, 379, 2417-2428.	27.0	287
88	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. British Journal of Cancer, 2018, 119, 801-807.	6.4	29
89	The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD. BMC Cancer, 2018, 18, 788.	2.6	8
90	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 1404-1416.	10.7	105

#	ARTICLE	IF	CITATIONS
91	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. <i>Lancet Oncology</i> , The, 2018, 19, e459-e469.	10.7	66
92	The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 2.	1.9	36
93	Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. <i>Clinical Trials</i> , 2018, 15, 624-630.	1.6	42
94	Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 44-52.	0.8	31
95	Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. <i>JMIR Human Factors</i> , 2018, 5, e10070.	2.0	20
96	Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study. <i>Blood</i> , 2018, 132, 2290-2290.	1.4	0
97	Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 735-743.	2.5	36
98	Translating Cancer Surveillance Data Into Effective Public Health Interventions. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 365.	7.4	25
99	Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 96-112.	1.6	1,454
100	Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 759-766.	1.2	35
101	Patient-Reported Outcomes "Harnessing Patients' Voices to Improve Clinical Care. <i>New England Journal of Medicine</i> , 2017, 376, 105-108.	27.0	426
102	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043.	7.1	98
103	The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery. <i>Current Oncology Reports</i> , 2017, 19, 12.	4.0	10
104	Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 409-418.	0.8	87
105	Patient-Reported Physical Function Measures in Cancer Clinical Trials. <i>Epidemiologic Reviews</i> , 2017, 39, 59-70.	3.5	29
106	Evaluating Alternative Payment Models in Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2123.	7.4	2
107	Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 197.	7.4	1,509
108	Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. <i>Clinical Trials</i> , 2017, 14, 255-263.	1.6	58

#	ARTICLE	IF	CITATIONS
109	Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 850-857.	0.8	43
110	The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. <i>Quality of Life Research</i> , 2017, 26, 2763-2772.	3.1	51
111	Appropriate Use of Antiemetics to Prevent Chemotherapy-Induced Nausea and Vomiting. <i>JAMA Oncology</i> , 2017, 3, 307.	7.1	1
112	Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 738.	7.1	53
113	The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 460-466.	3.8	31
114	Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients. <i>Journal of Patient-Reported Outcomes</i> , 2017, 1, 1.	1.9	52
115	Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of Patient-Reported Outcomes</i> , 2017, 1, 8.	1.9	44
116	From Intuition to Execution: Realizing the Potential of Wearables in Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, 90-92.	2.5	7
117	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	1.6	454
118	Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2017, 35, 1952-1964.	1.6	53
119	The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 460-466.	3.8	28
120	Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 67-73.	3.8	196
121	Implementation of Symptom Questionnaires Into Oncology Workflow. <i>Journal of Oncology Practice</i> , 2016, 12, 859-862.	2.5	12
122	Clinical Benefits Associated With Medicaid Coverage Before Diagnosis of Gynecologic Cancers. <i>Journal of Oncology Practice</i> , 2016, 12, e724-e733.	2.5	9
123	Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 753-758.	5.0	20
124	It's a long shot, but it just might work! Perspectives on the future of medicine. <i>BMC Medicine</i> , 2016, 14, 176.	5.5	17
125	Leveraging Emerging Technologies and the "Internet of Things" to Improve the Quality of Cancer Care. <i>Journal of Oncology Practice</i> , 2016, 12, 863-866.	2.5	28
126	Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. <i>Clinical Therapeutics</i> , 2016, 38, 821-830.	2.5	77

#	ARTICLE	IF	CITATIONS
127	Toward a Patient-Centered Value Framework in Oncology. JAMA - Journal of the American Medical Association, 2016, 315, 2073.	7.4	28
128	Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of Pain and Symptom Management, 2016, 52, 292-297.	1.2	32
129	Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clinical Trials, 2016, 13, 331-337.	1.6	40
130	Evaluation of pedometry as a patient-centered outcome in patients undergoing hematopoietic cell transplant (HCT): a comparison of pedometry and patient reports of symptoms, health, and quality of life. Quality of Life Research, 2016, 25, 535-546.	3.1	54
131	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of Thoracic Oncology, 2016, 11, 890-899.	1.1	4
132	Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 517.	2.2	93
133	Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Supportive Care in Cancer, 2016, 24, 2843-2851.	2.2	28
134	All together now: findings from a PCORI workshop to align patient-reported outcomes in the electronic health record. Journal of Comparative Effectiveness Research, 2016, 5, 561-567.	1.4	18
135	Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life. Gynecologic Oncology, 2016, 143, 362-366.	1.4	41
136	Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. Supportive Care in Cancer, 2016, 24, 4839-4847.	2.2	11
137	Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology. JAMA - Journal of the American Medical Association, 2016, 316, 1541.	7.4	18
138	Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncology, 2016, 2, 1628.	7.1	106
139	Reply to K. Kroenke et al. Journal of Clinical Oncology, 2016, 34, 3352-3352.	1.6	2
140	Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina. Cancer, 2016, 122, 3041-3050.	4.1	10
141	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, The, 2016, 17, e510-e514.	10.7	158
142	Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health and Quality of Life Outcomes, 2016, 14, 24.	2.4	91
143	The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Supportive Care in Cancer, 2016, 24, 3669-3676.	2.2	249
144	Using patient-reported outcome measures as quality indicators in routine cancer care. Cancer, 2016, 122, 355-357.	4.1	26

#	ARTICLE	IF	CITATIONS
145	Missing Patientsâ€™ Symptoms in Cancer Care Deliveryâ€”The Importance of Patient-Reported Outcomes. <i>JAMA Oncology</i> , 2016, 2, 433.	7.1	36
146	Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 319-325.	27.6	179
147	Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-565.	1.6	1,746
148	Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: A prospective feasibility study. <i>Advances in Radiation Oncology</i> , 2016, 1, 115-121.	1.2	48
149	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
150	Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 351-359.	2.5	14
151	Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper. <i>Quality of Life Research</i> , 2016, 25, 1123-1130.	3.1	13
152	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2016, 34, 381-386.	1.6	173
153	Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 148-154.	0.1	9
154	Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Instituteâ€™s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 67-73.	3.8	54
155	Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review. <i>JAMA Oncology</i> , 2015, 1, 375.	7.1	105
156	Development of the US NCI patient-reported outcomes version of the common terminology criteria for adverse events. <i>Annals of Oncology</i> , 2015, 26, vii26.	1.2	1
157	Gynecologic cancer outcomes in the elderly poor: A populationâ€‘based study. <i>Cancer</i> , 2015, 121, 3591-3599.	4.1	22
158	MR/Ultrasound Fusionâ€‘Guided Biopsy in Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 367.	7.4	1
159	Incorporating the patientâ€™s voice into electronic health records through patient-reported outcomes as the â€‘review of systemsâ€™. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 914-916.	4.4	41
160	Reply to E. Grunfeld. <i>Journal of Oncology Practice</i> , 2015, 11, 347-347.	2.5	0
161	The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review. <i>Supportive Care in Cancer</i> , 2015, 23, 3645-3652.	2.2	44
162	Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Oncology Nursing</i> , 2015, 19, 66-74.	2.1	27

#	ARTICLE	IF	CITATIONS
163	Potential and Challenges of Patient-Generated Health Data for High-Quality Cancer Care. <i>Journal of Oncology Practice</i> , 2015, 11, 195-197.	2.5	39
164	Models of Cancer Survivorship Care: Overview and Summary of Current Evidence. <i>Journal of Oncology Practice</i> , 2015, 11, e19-e27.	2.5	148
165	Big Data Infrastructure for Cancer Outcomes Research: Implications for the Practicing Oncologist. <i>Journal of Oncology Practice</i> , 2015, 11, 207-208.	2.5	7
166	Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs). <i>Value in Health</i> , 2015, 18, 493-504.	0.3	103
167	Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure. <i>Oncologist</i> , 2015, 20, 516-522.	3.7	23
168	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. <i>European Urology</i> , 2015, 68, 891-898.	1.9	91
169	Emerging uses of patient generated health data in clinical research. <i>Molecular Oncology</i> , 2015, 9, 1018-1024.	4.6	77
170	Comparison of Seven-Day and Repeated 24-Hour Recall of Symptoms in the First 100 Days After Hematopoietic Cell Transplantation. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 513-520.	1.2	10
171	Patient-related outcomes for metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2015, 16, 477-478.	10.7	1
172	Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>JAMA Oncology</i> , 2015, 1, 1051.	7.1	581
173	The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data. <i>Oncologist</i> , 2015, 20, 464-e20.	3.7	79
174	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e1-386.e6.	1.6	15
175	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	1.9	35
176	Statewide Geographic Variation and Impact of Center Expertise upon Outcomes for Adults with Acute Myeloid Leukemia (AML) in North Carolina. <i>Blood</i> , 2015, 126, 4479-4479.	1.4	0
177	The Rationale for Collecting Patient-Reported Symptoms during Routine Chemotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 161-165.	3.8	28
178	Cancer Care Research in North Carolina. <i>North Carolina Medical Journal</i> , 2014, 75, 248-252.	0.2	1
179	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3436-3448.	1.6	201
180	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3391-3399.	1.6	110

#	ARTICLE	IF	CITATIONS
181	Patient-Reported Outcome Performance Measures in Oncology. <i>Journal of Oncology Practice</i> , 2014, 10, 209-211.	2.5	79
182	The PCORI Perspective on Patient-Centered Outcomes Research. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1513.	7.4	424
183	Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju129-dju129.	6.3	245
184	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the National Cancer Institute</i> , 2014, 106, dju244-dju244.	6.3	689
185	Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective. <i>Cancer</i> , 2014, 120, 761-767.	4.1	29
186	Review of Electronic Patient-Reported Outcomes Systems Used in Cancer Clinical Care. <i>Journal of Oncology Practice</i> , 2014, 10, e215-e222.	2.5	257
187	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2014, 10, e418-e420.	2.5	7
188	Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Quality of Life Research</i> , 2014, 23, 257-269.	3.1	117
189	New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment. <i>Annual Review of Medicine</i> , 2014, 65, 307-317.	12.2	112
190	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , 2014, 15, 1147-1156.	10.7	181
191	Patient-Reported Outcomes in Clinical Trials of Rare Diseases. <i>Journal of General Internal Medicine</i> , 2014, 29, 801-803.	2.6	47
192	Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2740-2754.	1.5	23
193	An Evidence-Based Systematic Review of Elderberry and Elderflower (<i>Sambucus nigra</i>) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2014, 11, 80-120.	2.6	75
194	Big Data for Population-Based Cancer Research. <i>North Carolina Medical Journal</i> , 2014, 75, 265-269.	0.2	43
195	Interval Exercise Training (IET) Is Feasible and May Improve Cardiorespiratory Performance Prior to Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2611-2611.	1.4	3
196	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. <i>Seminars in Oncology</i> , 2013, 40, 375-392.	2.2	34
197	A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. <i>Supportive Care in Cancer</i> , 2013, 21, 1525-1550.	2.2	248
198	Systematic Collection of Patient-Reported Adverse Drug Reactions: A Path to Patient-Centred Pharmacovigilance. <i>Drug Safety</i> , 2013, 36, 277-278.	3.2	16

#	ARTICLE	IF	CITATIONS
199	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1193-1199.	10.7	142
200	Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance. <i>Drug Safety</i> , 2013, 36, 1129-1149.	3.2	84
201	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	27.0	2,412
202	Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 450-459.	2.0	44
203	Toward Patient-Centered Drug Development in Oncology. <i>New England Journal of Medicine</i> , 2013, 369, 397-400.	27.0	118
204	Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure. <i>Journal of Oncology Practice</i> , 2013, 9, 223-229.	2.5	29
205	Harnessing Technology to Improve Clinical Trials: Study of Real-Time Informatics to Collect Data, Toxicities, Image Response Assessments, and Patient-Reported Outcomes in a Phase II Clinical Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2004-2009.	1.6	38
206	Standards for Patient-Reported Outcome-Based Performance Measures. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 139.	7.4	115
207	Patients' Responsibility to Participate in Decision Making and Research. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2331.	7.4	65
208	Seaweed, Kelp, Bladderwrack (<i>Fucus vesiculosus</i>): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. <i>Alternative and Complementary Therapies</i> , 2013, 19, 217-230.	0.1	3
209	Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2580-2585.	1.6	134
210	Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses. <i>Journal of Clinical Oncology</i> , 2013, 31, 9618-9618.	1.6	2
211	Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 4249-4255.	1.6	413
212	American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review-Based Consensus Methodology. <i>Journal of Clinical Oncology</i> , 2012, 30, 3136-3140.	1.6	146
213	Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion. <i>Journal of Oncology Practice</i> , 2012, 8, 315-317.	2.5	9
214	Reliability of adverse symptom event reporting by clinicians. <i>Quality of Life Research</i> , 2012, 21, 1159-1164.	3.1	186
215	A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcome system in assessing patient recovery after major gynecologic cancer surgery. <i>Gynecologic Oncology</i> , 2012, 127, 273-277.	1.4	65
216	An Evidence-Based Systematic Review of Vitamin A by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2012, 9, 299-416.	2.6	9

#	ARTICLE	IF	CITATIONS
217	Hops (<i>Humulus lupulus</i>): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. <i>Alternative and Complementary Therapies</i> , 2012, 18, 98-108.	0.1	0
218	Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. <i>Pain Medicine</i> , 2012, 13, 1417-1424.	1.9	17
219	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217.	10.7	254
220	Beyond the FDA PRO Guidance: Steps toward Integrating Meaningful Patient-Reported Outcomes into Regulatory Trials and US Drug Labels. <i>Value in Health</i> , 2012, 15, 401-403.	0.3	48
221	Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 532-540.	3.8	24
222	Capturing the Patient Perspective: Patient-Reported Outcomes as Clinical Trial Endpoints. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 139-144.	3.8	18
223	How Do You Know If You Are Any Good? A Surgeon Performance Feedback System for the Outcomes of Radical Prostatectomy. <i>European Urology</i> , 2012, 61, 284-289.	1.9	28
224	Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5	0.3	17
225	Electronic patient-reported outcome systems in oncology clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 336-347.	329.8	279
226	Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. <i>Cancer</i> , 2012, 118, 1664-1674.	4.1	81
227	Turmeric(<i>Curcuma longa</i>): An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. <i>Alternative and Complementary Therapies</i> , 2011, 17, 225-236.	0.1	6
228	Assuring the Patient Centeredness of Patient-Reported Outcomes: Content Validity in Medical Product Development and Comparative Effectiveness Research. <i>Value in Health</i> , 2011, 14, 965-966.	0.3	18
229	An Evidence-Based Systematic Review of <i>Gymnema</i> (<i>Gymnema sylvestre</i> R. Br.) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2011, 8, 311-330.	2.6	16
230	End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, 3695-3704.	1.6	202
231	Electronic Toxicity Monitoring and Patient-Reported Outcomes. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 231-234.	2.0	46
232	Clinical Cancer Informatics. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 195-196.	2.0	6
233	Using Confirmatory Factor Analysis to Evaluate Construct Validity of the Brief Pain Inventory (BPI). <i>Journal of Pain and Symptom Management</i> , 2011, 41, 558-565.	1.2	217
234	Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. <i>Pain</i> , 2011, 152, 1705-1708.	4.2	36

#	ARTICLE	IF	CITATIONS
235	The king's foot of patient-reported outcomes: current practices and new developments for the measurement of change. <i>Quality of Life Research</i> , 2011, 20, 1159-1167.	3.1	29
236	Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Translational Behavioral Medicine</i> , 2011, 1, 110-122.	2.4	43
237	Supporting Clinical Practice Decisions With Real-Time Patient-Reported Outcomes. <i>Journal of Clinical Oncology</i> , 2011, 29, 954-956.	1.6	124
238	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Oncology Practice</i> , 2011, 7, 395-398.	2.5	52
239	Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators. <i>Clinical Cancer Research</i> , 2011, 17, 222-228.	7.0	34
240	Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1808-1810.	6.3	99
241	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2011, 29, 4189-4198.	1.6	822
242	Commentary: Should Cost and Comparative Value of Treatments Be Considered in Clinical Practice Guidelines?. <i>Journal of Oncology Practice</i> , 2011, 7, 398-401.	2.5	6
243	Commentary: Encouraging Clinicians to Incorporate Longitudinal Patient-Reported Symptoms in Routine Clinical Practice. <i>Journal of Oncology Practice</i> , 2011, 7, 23-25.	2.5	15
244	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. <i>Supportive Care in Cancer</i> , 2010, 18, 509-522.	2.2	142
245	Validation study of a web-based assessment of functional recovery after radical prostatectomy. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 82.	2.4	59
246	The Brief Pain Inventory and Its "Pain At Its Worst in the Last 24 Hours" Item: Clinical Trial Endpoint Considerations. <i>Pain Medicine</i> , 2010, 11, 337-346.	1.9	161
247	A Review of Quality of Care Evaluation for the Palliation of Dyspnea. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 534-538.	5.6	68
248	The Missing Voice of Patients in Drug-Safety Reporting. <i>New England Journal of Medicine</i> , 2010, 362, 865-869.	27.0	524
249	American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3388-3404.	1.6	246
250	A Strategy To Advance the Evidence Base in Palliative Medicine: Formation of a Palliative Care Research Cooperative Group. <i>Journal of Palliative Medicine</i> , 2010, 13, 1407-1413.	1.1	81
251	An Evidence-Based Systematic Review of Bilberry (<i>Vaccinium myrtillus</i>) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2009, 6, 162-200.	2.6	20
252	Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1624-1632.	6.3	514

#	ARTICLE	IF	CITATIONS
253	Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report. <i>Value in Health</i> , 2009, 12, 419-429.	0.3	430
254	Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 51-57.	1.9	21
255	Electronic patient-reported outcomes for collecting sensitive information from patients. <i>The Journal of Supportive Oncology</i> , 2009, 7, 98-9.	2.3	17
256	An Evidence-Based Systematic Review of Passion Flower (<i>Passiflora Incarnata</i> L.) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2008, 5, 310-340.	2.6	1
257	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	1.6	1,960
258	Natural Standard Professional Monograph. <i>Journal of Dietary Supplements</i> , 2008, 5, 117-146.	2.6	8
259	An Evidence-Based Systematic Review of Blessed Thistle (<i>Cnicus benedictus</i>) by the Natural Standard Research Collaboration. <i>Journal of Dietary Supplements</i> , 2008, 5, 422-437.	2.6	3
260	Peppermint (<i>Mentha Xpiperita</i>). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2008, 7, 91-143.	0.1	11
261	Against Diagnosis. <i>Annals of Internal Medicine</i> , 2008, 149, 200.	3.9	58
262	Patient-Reported Outcomes and the Evolution of Adverse Event Reporting in Oncology. <i>Journal of Clinical Oncology</i> , 2007, 25, 5121-5127.	1.6	278
263	Expectations for specialized knowledge in oncology: time to reassess. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 263-263.	4.3	0
264	Long-Term Toxicity Monitoring via Electronic Patient-Reported Outcomes in Patients Receiving Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 5374-5380.	1.6	173
265	American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5313-5318.	1.6	65
266	Targeted drugs for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2007, 370, 2071-2073.	13.7	79
267	Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2007, 14, 264-268.	4.4	108
268	An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 719-728.	2.4	35
269	Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. <i>Lancet Oncology, The</i> , 2006, 7, 903-909.	10.7	512
270	Marigold (<i>Calendula officinalis</i> L.). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2006, 6, 135-159.	0.1	50

#	ARTICLE	IF	CITATIONS
271	Evidence-Based Systematic Review of Saw Palmetto by the Natural Standard Research Collaboration*. Society for Integrative Oncology, 2006, 04, 170.	0.7	11
272	Devil's Claw (<i>Harpagophytum procumbens</i> DC): an evidence-based systematic review by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2006, 6, 89-126.	0.1	10
273	Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy. Journal of Clinical Oncology, 2005, 23, 3552-3561.	1.6	267
274	Safety review of kava (<i>Piper methysticum</i>) by the Natural Standard Research Collaboration. Expert Opinion on Drug Safety, 2005, 4, 779-794.	2.4	58
275	Guggul for hyperlipidemia: A review by the Natural Standard Research Collaboration. Complementary Therapies in Medicine, 2005, 13, 279-290.	2.7	91
276	Safety Assurances for Dietary Supplements. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2005, 5, 3-15.	0.1	3
277	Safety assurances for dietary supplements policy issues and new research paradigms. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2005, 5, 3-15.	0.1	4
278	Evidence-based systematic review of dandelion (<i>Taraxacum officinale</i>) by natural standard research collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2005, 5, 79-93.	0.1	16
279	An evidence-based systemic review <i>Echinacea</i> <i>E. angustifolia</i> DC, <i>E. pallida</i> , <i>E. purpurea</i> by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2005, 5, 57-88.	0.1	2
280	Butterbur: an evidence-based systematic review by the natural standard research collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2005, 5, 119-43.	0.1	7
281	Lemon balm (<i>Melissa officinalis</i> L.): an evidence-based systematic review by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2005, 5, 71-114.	0.1	13
282	An Evidence-Based Systematic Review of Belladonna by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2004, 4, 61-90.	0.1	19
283	Use of information resources by patients with cancer and their companions. Cancer, 2004, 100, 2476-2483.	4.1	164
284	Thyme (<i>Thymus vulgaris</i> L.), thymol. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2004, 4, 49-67.	0.1	24
285	Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2004, 4, 63-83.	0.1	27
286	An evidence-based systematic review of belladonna by the natural standard research collaboration. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2004, 4, 61-90.	0.1	8
287	St. John's Wort: A Systematic Review of Adverse Effects and Drug Interactions for the Consultation Psychiatrist. Psychosomatics, 2003, 44, 271-282.	2.5	110
288	Bitter melon (<i>Momordica charantia</i>): A review of efficacy and safety. American Journal of Health-System Pharmacy, 2003, 60, 356-359.	1.0	304

#	ARTICLE	IF	CITATIONS
289	Alfalfa (<i>Medicago sativa</i> L.). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2003, 3, 69-90.	0.1	7
290	Therapeutic applications of fenugreek. <i>Alternative Medicine Review</i> , 2003, 8, 20-7.	3.3	155
291	Marshmallow (<i>Althaea officinalis</i> L.) Monograph. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2003, 3, 71-81.	0.1	2
292	Wild Yam (<i>Dioscoreaceae</i>). <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2003, 3, 77-91.	0.1	5
293	Kava monograph: a clinical decision support tool. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2002, 2, 65-91.	0.1	2
294	Horse chestnut: a multidisciplinary clinical review. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2002, 2, 71-85.	0.1	7